Neonatal Gene Therapy With a Gamma Retroviral Vector in Mucopolysaccharidosis VI Cats

作者：Ponder Katherine P^*; O'Malley Thomas M; Wang Ping; O'Donnell Patricia A; Traas Anne M; Knox Van W; Aguirre Gustavo A; Ellinwood N Matthew; Metcalf Jason A; Wang Bin; Parkinson Lawrence Emma J; Sleeper Meg M; Brooks Doug A; Hopwood John J; Haskins Mark E

来源：Molecular Therapy, 2012, 20(5): 898-907.

DOI：10.1038/mt.2012.9

Mucopolysaccharidosis (MPS) VI is due to a deficiency in the activity of N-acetylgalactosamine 4-sulfatase (4S), also known as arylsulfatase B. Previously, retroviral vector (RV)-mediated neonatal gene therapy reduced the clinical manifestations of MPS I and MPS VII in mice and dogs. However, sulfatases require post-translational modification by sulfatase-modifying factors. MPS VI cats were injected intravenously (i.v.) with a gamma RV-expressing feline 4S, resulting in 5 +/- 3 copies of RV per 100 cells in liver. Liver and serum 4S activity were 1,450 +/- 1,720 U/mg (26-fold normal) and 107 +/- 60 U/ml (13-fold normal), respectively, and were directly proportional to the liver 4S protein levels for individual cats. This study suggests that sulfatase-modifying factor (SUMF) activity in liver was sufficient to result in active enzyme despite overexpression of 4S. RV-treated MPS VI cats achieved higher body weights and longer appendicular skeleton lengths, had reduced articular cartilage erosion, and reduced aortic valve thickening and aortic dilatation compared with untreated MPS VI cats, although cervical vertebral bone lengths were not improved. This demonstrates that therapeutic expression of a functional sulfatase protein can be achieved with neonatal gene therapy using a gamma RV, but some aspects of bone disease remain difficult to treat.

• 出版日期2012-5